Q3 2026 Earnings Call March 4, 2026 7:00 PM ESTCompany ParticipantsEric Schmiedchen - Head of Investor RelationsAlfred Felder ...
Joseph Todisco EVP and Chief Operating Officer — Elizabeth Masson-Hurlburt EVP and Chief Financial Officer — Susan Blum ...
Label expansion strategy -- The company is actively pursuing a broad label for Tadaraben to include all Stargardt disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results